Skip to main content
SpringerLink
Log in

SPC 3

  • Section 2: HIV Fusion Inhibitor
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Barbouche R, Fenouillet E, Papandreou MJ, et al. Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials. J Peptide Res 1998 Oct; 52: 283–8

    Article  CAS  Google Scholar 

  2. Columbia Labs AIDS therapy SPC3 entering phase II/III clinicals. FDC Reports (Pink Sheet) 1995 Feb 27

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

SPC 3. Drugs R&D 2, 352 (1999). https://doi.org/10.2165/00126839-199902050-00018

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902050-00018

Keywords

Search

Navigation